Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jun 1, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
21.6%
-43.2% vs 52w high · +0.4% 1mo
Price (last ~year)
Novo Nordisk (NVO) reported 24.0% year-over-year revenue growth and 67.1% earnings growth, supported by an 83.2% gross margin and a $201.95 billion market capitalization. The company is advancing its cardiometabolic pipeline, recently securing European regulatory support for an oral version of its obesity drug, Wegovy, while maintaining a DKK 15 billion share buyback program. Financial liquidity is underscored by $21.13 billion in cash and a debt-to-EBITDA ratio of 0.8x.
Valuation
- Market cap
- $201.95B
- P/E
- 10.7
- PEG
- 3.363
- P/B
- 6.4
- P/S
- 0.616
- EV/EBITDA
- 7.91
- Beta
- 0.348
- Analyst target
- $46.9
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $44.06
- 1-month
- +0.4%
- 3-month
- +16.7%
- RSI (14)
- 37
- vs SMA200
- -7.4%
- 52-wk position
- 21.6% -43.2% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $37.30B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $31.44B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Somewhat-Bullish Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus · 2026-05-29
- Bullish Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions · 2026-05-27
- Bullish Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme · 2026-05-27
- Bullish European Regulator Backs Novo Nordisk’s Wegovy Weight-Loss Pill · 2026-05-22
- Bullish Novo gets EU backing for higher-dose Wegovy in single-dose pen · 2026-05-22
- Bullish Novo Nordisk wins EU endorsement for Wegovy pill (NVO:NYSE) · 2026-05-22
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)